CClinicalTrials.gg
CompletedNCT01869647Updated Mar 20, 2020Results posted

Feasibility and Impact of a Decision Rule for Imaging of Emergency Department Patients With Suspected Kidney Stone

An interventional study of Ultra low dose CT scan and Regular CT or Low Dose CT scan in Kidney Stones, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-20.

Sponsored by Yale University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
264
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is the third phase (feasibility and impact) of a three-phase project designed to derive, validate and test the feasibility and impact of implementing clinical decision support to safely limit the use of Computerized Tomography (CT) and its accompanying radiation and cost in emergency department patients with suspected renal colic.

Hypothesis: Using a before and after model, integration of a clinical prediction rule into decisions about imaging in patients with suspected renal colic will result in a reduction of between 25-50% of radiation received from CT scanning in this population, without adverse affects on patient-centered outcomes.

Read the detailed description

Patients that a clinician deems a CT Flank Pain Protocol for suspected kidney stone is warranted based on their usual practice will be eligible for enrollment. Clinicians will be encouraged to page the Research Associate (RA) prior to ordering the CT, and an automatic page will go out for all CT flank pain protocols that are ordered via EPIC. RAs will approach eligible subjects for written informed consent. Subjects who are incapable or unwilling to provide informed consent, including non-English speaking patients will be excluded.

Following written informed consent, eligibility for the S.T.O.N.E. score will be determined.

Subjects that consent to enrollment but have exclusion criteria will be enrolled observationally to determine the performance of the S.T.O.N.E. score and outcomes in these groups, but will not be eligible for alternate imaging pathways.

Subjects who do not have any of the above exclusion criteria will be placed in one of three groups based on the S.T.O.N.E. score (which may be supplemented by gestalt clinician pre-test probability and/or point-of-care ultrasound for hydronephrosis). The groups are low, moderate, or high and correspond to the likelihood of the patient having a kidney stone as described in results from phases I and II.Subjects in the "high" likelihood of stone group will be eligible to get either Ultra Low Dose Computerized Tomography (ULDCT) or "expectant management". The choice will be determined by the primary clinician in conjunction with the patient. If ULDCT is elected, the scan will be read diagnostically by the radiologist and the clinician will treat the patient based on these results. If the expectant management option is chosen, no CT will be done during the ED visit and they will be treated as if they have a kidney stone. We will attempt to contact these patients at \~1 week after their ED visit, and they will also have the option to contact our study team. If symptoms are persistent for a week or more, subjects may of course pursue further clinical care with the clinician of their choice and this will not be billed to the study.

Subjects in the "moderate" likelihood of stone group will be given the option to receive either a standard dose CT or ULDCT. Again, the decision of which imaging option to choose will be made by the primary clinician in conjunction with the patient.

In the "low" likelihood of stone group the RA will present the data from the stone score to the physician and explain that patient is unlikely to have a kidney stone and they will be advised that probability of a stone is very low and that alternate imaging choices may be warranted. If they still choose to order a CT Flank Pain Protocol they will be asked to provide reasoning and the patient will receive a regular dose CT Flank Pain Protocol.

All subjects will be followed during their Emergency Department (ED) course and follow-up care (records in EPIC), with an attempt to contact the patient at \~90 days after the initial ED visit. Outcomes will include the number of eligible patients that receive regular dose CT, ULDCT, or the expectant management option. Radiation dose received will be measured with comparison of both the expected radiation dose if regular CT had been performed in all eligible patients and using a before and after model from phases I and II. We will also follow all patients to determine the prevalence and timing of diagnosis and/or intervention for kidney stone or other pathology. We will qualitatively compare the prevalence of alternative causes of symptoms and incidental findings (and follow-up) for regular and low dose CTs.

02

Conditions studied

  • Kidney Stones

Keywords

  • kidney stones
03

In context

Kidney Calculi

598 studies on the registry are indexed under Kidney Calculi; 163 are open to participants now.

This study's enrollment of 264 is above the median of 90 across 461 interventional studies indexed under Kidney Calculi.

Browse Kidney Calculi studies →

Lead sponsor

Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.

Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients 18 or older who present to the adult YNHH ED, Saint Raphael Campus ED or SMC ED in whom renal colic is suspected upon presentation, and the physician intends to order a CT FPP study for suspicion of a kidney stone. Members of all ethnic and racial groups are eligible.

Exclusion criteria

Exclusion Criteria:

  • Exclusion Criteria Patients will be excluded for any one of the following reasons: patients that are

    1. pregnant
    2. prisoners
    3. unable or unwilling to consent (including non-English speaking)
    4. with a history or physical evidence of recent trauma
    5. renal colic not suspected by clinician

Patients with the following will not be eligible for alternate imaging, but will be enrolled observationally:

  1. evidence of infection (leucocytes in urine, fever)
  2. pre-existing renal disease (including creatinine 1.5 or greater)
  3. prior urologic intervention
  4. active malignancy (within last 6 months)
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
264 participants (actual)

Study arms

  • Active comparator
    "high" likelihood of stone group

    Subjects in the "high" likelihood of stone group will be eligible to get either ULDCT or "expectant management". The choice will be determined by the primary clinician in conjunction with the patient. If ULDCT is elected, the scan will be read diagnostically by the radiologist and the clinician will treat the patient based on these results. If the expectant management option is chosen, no CT will be done during the ED visit and they will be treated as if they have a kidney stone. Participants in this group will receive Ultra low dose CT scan.

    Radiation: Ultra low dose CT scan

  • Active comparator
    "moderate" likelihood of stone group

    Subjects in the "moderate" likelihood of stone group will be given the option to receive either a standard dose CT or ULDCT. Again, the decision of which imaging option to choose will be made by the primary clinician in conjunction with the patient. Participants in this group will receive regular or low dose CT scan.

    Radiation: Regular CT or Low Dose CT scan

  • Active comparator
    "low" likelihood of stone group

    In the "low" likelihood of stone group the RA will present the data from the stone score to the physician and explain that patient is unlikely to have a kidney stone and they will be advised that probability of a stone is very low and that alternate imaging choices may be warranted. If they still choose to order a CT Flank Pain Protocol they will be asked to provide reasoning and the patient will receive a regular dose CT Flank Pain Protocol. Participants in this group will not receive imaging.

    Radiation: No imaging

Interventions

  • RadiationUltra low dose CT scan

    Ultra low dose CT scan

  • RadiationRegular CT or Low Dose CT scan

    Regular CT or Low Dose CT scan

  • RadiationNo imaging

    No imaging

06

What researchers measure

Primary outcomes

  1. Radiation Exposure (Dose-Length-Product) at Baseline

    Radiation exposure at baseline was collected using the mean dose length product mGy\*cm.

    Time frame: Baseline (at enrollment)

Secondary outcomes

  1. Prevalence of Urological Intervention

    This measure presents the prevalence of participants needing urological intervention in each arm within 90 days.

    Time frame: 90 days

07

Results

Posted Sep 21, 2016

Participant flow

Participant flow — Overall Study
Milestone"High" Likelihood of Stone Group"Moderate" Likelihood of Stone Group"Low" Likelihood of Stone Group
Started6613662
Completed6513062
Not completed160

Outcome measures

PrimaryRadiation Exposure (Dose-Length-Product) at Baseline

Radiation exposure at baseline was collected using the mean dose length product mGy\*cm.

Time frame:
Baseline (at enrollment)
Reported as:
Mean · mGy*cm
Radiation Exposure (Dose-Length-Product) at Baseline
mGy*cm"High" Likelihood of Stone Group"Moderate" Likelihood of Stone Group"Low" Likelihood of Stone Group
Radiation Exposure (Dose-Length-Product) at Baseline293.5 (210.5 to 377)482.1 (398.2 to 566)915.99 (834.2 to 998)
SecondaryPrevalence of Urological Intervention

This measure presents the prevalence of participants needing urological intervention in each arm within 90 days.

Time frame:
90 days
Reported as:
Number · participants
Prevalence of Urological Intervention
participants"High" Likelihood of Stone Group"Moderate" Likelihood of Stone Group"Low" Likelihood of Stone Group
Prevalence of Urological Intervention19243

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
"High" Likelihood of Stone Group—0/66 (0%)0/66 (0%)
"Moderate" Likelihood of Stone Group—0/136 (0%)0/136 (0%)
"Low" Likelihood of Stone Group—0/62 (0%)0/62 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)"High" Likelihood of Stone Group"Moderate" Likelihood of Stone Group"Low" Likelihood of Stone GroupTotal
<=18 years0000
Between 18 and 65 years6212954245
>=65 years47819
Age, Continuous
Age, Continuous(years)"High" Likelihood of Stone Group"Moderate" Likelihood of Stone Group"Low" Likelihood of Stone GroupTotal
Mean42.2 ± 14.144.0 ± 13.746.1 ± 14.744.0 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)"High" Likelihood of Stone Group"Moderate" Likelihood of Stone Group"Low" Likelihood of Stone GroupTotal
Female155845118
Male517817146
Region of Enrollment
Region of Enrollment(participants)"High" Likelihood of Stone Group"Moderate" Likelihood of Stone Group"Low" Likelihood of Stone GroupTotal
United States6613662264
08

Study locations

1 site
  • Yale University
    New Haven, Connecticut 06519, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01869647
Lead sponsor
Yale University
Collaborators
Agency for Healthcare Research and Quality (AHRQ)
Responsible party
Sponsor
First posted
Jun 5, 2013
Start date
Apr 2013
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Sep 21, 2016
Last update
Mar 20, 2020

Study contacts

Christopher L Moore, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion